Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis
Matrix metalloproteinase 9 (MMP-9) is a risk factor for cardiovascular events. The serum MMP-9 levels were measured before and 2 weeks after treatment with infliximab (3 mg/kg) in 12 rheumatoid arthritis (RA) patients. The serum average MMP-9 level was 238.5 ng/ml before treatment with infliximab in...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2012-01-01
|
| Series: | Journal of Pharmacological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861319304645 |
| _version_ | 1830161881931710464 |
|---|---|
| author | Takuya Kotani Tohru Takeuchi Shinji Takai Shuzo Yoshida Kenichiro Hata Koji Nagai Daisuke Wakura Kentaro Isoda Shigeki Makino Toshiaki Hanafusa |
| author_facet | Takuya Kotani Tohru Takeuchi Shinji Takai Shuzo Yoshida Kenichiro Hata Koji Nagai Daisuke Wakura Kentaro Isoda Shigeki Makino Toshiaki Hanafusa |
| author_sort | Takuya Kotani |
| collection | DOAJ |
| description | Matrix metalloproteinase 9 (MMP-9) is a risk factor for cardiovascular events. The serum MMP-9 levels were measured before and 2 weeks after treatment with infliximab (3 mg/kg) in 12 rheumatoid arthritis (RA) patients. The serum average MMP-9 level was 238.5 ng/ml before treatment with infliximab in RA patients (normal range: less than 43.8 ng/ml). Infliximab reduced the serum average MMP-9 level significantly (161.66 ng/ml, P = 0.0425). The serum MMP-9 level was high in the RA patients with active disease, and it was reduced by infliximab independently of the reduction in disease activity. Thus, infliximab may reduce the risk of cardiovascular events directly. Keywords:: rheumatoid arthritis, matrix metalloproteinase 9, acute coronary syndrome |
| first_indexed | 2024-12-17T15:09:29Z |
| format | Article |
| id | doaj.art-7aaab617a4484c08bee14e787de4a23f |
| institution | Directory Open Access Journal |
| issn | 1347-8613 |
| language | English |
| last_indexed | 2024-12-17T15:09:29Z |
| publishDate | 2012-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Pharmacological Sciences |
| spelling | doaj.art-7aaab617a4484c08bee14e787de4a23f2022-12-21T21:43:42ZengElsevierJournal of Pharmacological Sciences1347-86132012-01-0112015053Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid ArthritisTakuya Kotani0Tohru Takeuchi1Shinji Takai2Shuzo Yoshida3Kenichiro Hata4Koji Nagai5Daisuke Wakura6Kentaro Isoda7Shigeki Makino8Toshiaki Hanafusa9Department of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, JapanDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, Japan; Corresponding author. t-takeuchi@poh.osaka-med.ac.jpDepartment of Pharmacology, Osaka Medical College, Takatsuki, Osaka 569-8686, JapanDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, JapanDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, JapanDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, JapanDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, JapanDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, JapanDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, JapanDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka 569-8686, JapanMatrix metalloproteinase 9 (MMP-9) is a risk factor for cardiovascular events. The serum MMP-9 levels were measured before and 2 weeks after treatment with infliximab (3 mg/kg) in 12 rheumatoid arthritis (RA) patients. The serum average MMP-9 level was 238.5 ng/ml before treatment with infliximab in RA patients (normal range: less than 43.8 ng/ml). Infliximab reduced the serum average MMP-9 level significantly (161.66 ng/ml, P = 0.0425). The serum MMP-9 level was high in the RA patients with active disease, and it was reduced by infliximab independently of the reduction in disease activity. Thus, infliximab may reduce the risk of cardiovascular events directly. Keywords:: rheumatoid arthritis, matrix metalloproteinase 9, acute coronary syndromehttp://www.sciencedirect.com/science/article/pii/S1347861319304645 |
| spellingShingle | Takuya Kotani Tohru Takeuchi Shinji Takai Shuzo Yoshida Kenichiro Hata Koji Nagai Daisuke Wakura Kentaro Isoda Shigeki Makino Toshiaki Hanafusa Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis Journal of Pharmacological Sciences |
| title | Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis |
| title_full | Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis |
| title_fullStr | Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis |
| title_full_unstemmed | Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis |
| title_short | Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis |
| title_sort | serum levels of matrix metalloproteinase mmp 9 a risk factor for acute coronary syndrome are reduced independently of serum mmp 3 by anti tnf α antibody infliximab therapy in patients with rheumatoid arthritis |
| url | http://www.sciencedirect.com/science/article/pii/S1347861319304645 |
| work_keys_str_mv | AT takuyakotani serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT tohrutakeuchi serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT shinjitakai serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT shuzoyoshida serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT kenichirohata serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT kojinagai serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT daisukewakura serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT kentaroisoda serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT shigekimakino serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis AT toshiakihanafusa serumlevelsofmatrixmetalloproteinasemmp9ariskfactorforacutecoronarysyndromearereducedindependentlyofserummmp3byantitnfaantibodyinfliximabtherapyinpatientswithrheumatoidarthritis |